Related Experiment Videos
[Levamisol in the treatment of recurrent urinary tract infections]
Insights
Levamisole treatment improved cellular immunity in children with recurrent urinary tract infections. This immunomodulatory therapy helped prevent infection recurrence and enhanced immune responses.
Area of Science:
- Immunology
- Pediatrics
- Pharmacology
Background:
- Recurrent respiratory tract infections in children have been previously linked to improved outcomes with Levamisole.
- Children with recurrent urinary tract infections (UTIs) often exhibit diminished cellular immunity.
- Structural malformations were excluded in the study population.
Purpose of the Study:
- To investigate the efficacy of Levamisole in improving cellular immunity and preventing recurrent UTIs in children.
- To assess the impact of Levamisole on specific immune markers in pediatric patients.
Main Methods:
- A study involving 27 children with recurrent UTIs and diminished cellular immunity.
- Administration of Levamisole at 2.5 mg/kg/day, twice weekly for eight months.
- Evaluation of cellular immunity through lymphocyte blastic transformation, T lymphocyte rosettes, and skin tests.
Main Results:
- 21 out of 27 children experienced no recurrence of UTIs during the study period.
- 13 children showed significant improvement in cellular immunity markers.
- Elevated levels of secretory IgA in urine were observed in some participants.
Conclusions:
- Levamisole demonstrates potential as an immunomodulatory agent for managing recurrent UTIs in children.
- The drug appears effective in both preventing infection recurrence and enhancing cellular immune function.
- Further research into Levamisole's role in pediatric urological infections is warranted.
Abstract:
Levamisole, a widely used antihelminthic drug, possesses immunotropic properties. It has been proved that children with recurrent infections of the respiratory tract who were given the drug, were capable of preventing the repetition of the infections. Twenty-seven (27) children with recurrent urinary tract infections without structural malformations were studied and in all of them, a diminished cellular immunity was detected (blastic transformation of lymphocytes, rosettes of T lymphocytes and the skin tests). The drug was administered in doses of 2.5 mg/k/day, twice a week, for eight months. During the period of study, in 21 children repetition of the infections were not detected and in 13, a significant improvement of the cellular immunity was achieved. In some children it was possible to prove a rise of the IgA secretary in the urine.